BidaskClub upgraded shares of Pulse Biosciences (NASDAQ:PLSE) from a sell rating to a hold rating in a report published on Tuesday.
Separately, ValuEngine upgraded Pulse Biosciences from a sell rating to a hold rating in a research report on Sunday, December 31st.
Shares of PLSE stock opened at $18.91 on Tuesday. Pulse Biosciences has a twelve month low of $9.81 and a twelve month high of $39.50.
Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings results on Friday, March 16th. The company reported ($0.53) earnings per share for the quarter.
A number of hedge funds have recently made changes to their positions in the stock. Fore Capital LLC purchased a new position in Pulse Biosciences during the fourth quarter valued at approximately $236,000. Millennium Management LLC purchased a new position in Pulse Biosciences during the fourth quarter valued at approximately $290,000. Ladenburg Thalmann Financial Services Inc. purchased a new position in Pulse Biosciences during the fourth quarter valued at approximately $158,000. Deutsche Bank AG raised its position in Pulse Biosciences by 141.3% during the fourth quarter. Deutsche Bank AG now owns 20,305 shares of the company’s stock valued at $478,000 after acquiring an additional 11,890 shares in the last quarter. Finally, Alliancebernstein L.P. purchased a new position in Pulse Biosciences during the fourth quarter valued at approximately $248,000. Institutional investors own 10.84% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This article was reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at www.tickerreport.com/banking-finance/3373628/pulse-biosciences-plse-lifted-to-hold-at-bidaskclub.html.
Pulse Biosciences Company Profile
Pulse Biosciences, Inc, a clinical-stage medical technology company, develops therapeutic tissue treatment platform based on its proprietary nano-pulse stimulation (NPS) technology. Its NPS is a non-thermal, precise, and focal drug-free tissue treatment technology that initiates cell death within treated tissue used in oncology, dermatology/aesthetics, minimally invasive, and veterinary applications.